Denosumab Combined With PARP Inhibitors and Chemoradiotherapy for Treating Triple Negative Breast Cancer With Bone Metastasis: A Case Report

TL;DR

A patient with triple-negative breast cancer and bone metastasis showed improved outcomes with a combination of denosumab, PARP inhibitors, and chemoradiotherapy.

Contribution

This case report presents a novel combination therapy for TNBC with bone metastasis.

Findings

The treatment led to effective disease control and symptom improvement.

Imaging showed stabilization of bone lesions with no severe side effects.

Abstract

Triple‐negative breast cancer (TNBC) with bone metastasis is associated with poor prognosis and limited treatment options. Denosumab has shown efficacy in preventing skeletal‐related events, while PARP inhibitors have demonstrated promising activity in patients with homologous recombination deficiency.

We report a patient with TNBC and bone metastasis who received a combination treatment including denosumab, PARP inhibitors, and chemoradiotherapy. The treatment resulted in effective disease control and improvement of clinical symptoms. Imaging evaluation showed stabilization of bone lesions, and the patient tolerated the treatment well without severe adverse events.

This case suggests that the combination of denosumab with PARP inhibitors and chemoradiotherapy may provide a potential therapeutic strategy for TNBC patients with bone metastasis. Further studies are warranted to validate the efficacy and safety of this combined treatment approach.

Figures